Status:
COMPLETED
In-hospital Initiation of PCSK9 Inhibitor in Patients With Acute Myocardial Infarction
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University
Conditions:
Coronary Disease
Eligibility:
All Genders
18-80 years
Brief Summary
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to improve cardiovascular outcomes when added to conventional statin therapy. This study aims to investigate the effica...
Eligibility Criteria
Inclusion
- confirmed admission diagnosis of AMI and were defined based on the universal definition criteria by the American Cardiology College
Exclusion
- (1) severe noncardiac disease with an expected survival of less than 1 year and unwillingness to participate; (2) patients over the age of 80 years or living far away from the hospital's catchment area.
Key Trial Info
Start Date :
January 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2021
Estimated Enrollment :
7556 Patients enrolled
Trial Details
Trial ID
NCT05184530
Start Date
January 1 2016
End Date
December 1 2021
Last Update
January 11 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.